Abstract
Introduction
Chronic rhinosinusitis (CRS) can be defined as a group of disorders characterized by inflammation of the nose and paranasal sinus mucosa for at least 12 consecutive weeks. 1 The range of symptoms of CRS is broad; they include facial pain/pressure, congestion, nasal discharge, headache, fever, and hyposmia. 1, 2 A unified theory to explain the pathophysiology of these symptoms remains elusive despite multiple attempts to identify an underlying etiology. 3 However, a common thread among all patients with CRS is a persistent inflammation of the nasal and paranasal sinus mucosa. The mechanism that triggers this inflammation has yet to be determined, but it appears to be multifactorial. Several theories have surfaced over time, including those that implicate bacterial and/or fungal infection, biofilms, superantigens, allergy, dysfunction of the innate immune system, and anatomic defects. 1, 3, 4 Because of the lack of a confirmed cause, treatment options for CRS are varied; it includes topical and oral antibiotics, topical and oral steroids, nasal irrigation, antifungals, decongestants, mucolytics, antihista-LIU, RICHARDSON, BERNARD, CHURCH, SEIBERLING mines, leukotriene inhibitors, and surgery. 3, 5, 6 Therapy for CRS differs for patients with and without nasal polyps, the latter of whom are the focus of this study.
Traditionally, standard treatments were formulated on the presumption of an infectious cause, which led to the widespread use of antibiotics for the treatment of CRS without nasal polyps (CRSsNP). 7 However, multiple attempts to define the pathogenesis and microbiology of this entity have left us with conflicting data, providing little direction for treatment. 1 Despite the lack of compelling evidence regarding their efficacy, two of the most common treatments for CRSsNP continue to be antibiotics and steroids. [6] [7] [8] A survey of members of the American Rhinologic Society published in 2007 revealed that oral antibiotics were "almost always" prescribed (>90% of respondents) and that oral steroids were prescribed by 50 to 90% of respondents. 7 Both treatment modalities are recommended only as "options" in recently published reviews because of the lack of high-quality studies of their efficacy. 3, 8 Considering the paucity of robust data, we sought to compare the efficacy of an antibiotic alone, a steroid alone, and both together as the initial treatment for CRSsNP.
Patients and methods
We conducted a retrospective study of all patients who had been treated for sinusitis at the Loma Linda University Medical Center in California from January 2010 through January 2015. We reviewed the electronic medical records system in our Department of Otolaryngology-Head and Neck Surgery to identify diagnoses of chronic maxillary, frontal, ethmoid, sphenoid, and unspecified chronic sinusitis (ICD-9 codes 473.0, 473.1, 437.2, 437.3, and 437.9, respectively).
Our exclusion criteria were an age of less than 18 years, the presence of nasal polyps, a history of previous sinonasal surgery, and the use of an antibiotic or steroid within 4 weeks of a patient's initial visit. We also disqualified patients who had received an antibiotic prescription for less than 10 days at their initial visit and those who had less than 4 weeks of total follow-up. Finally, we denied eligibility to patients who had had a sinonasal or cranial neoplasm, cerebrospinal fluid rhinorrhea, cystic fibrosis, a bone or cartilage disorder, or a history of sinonasal or cranial trauma, vasculitides, or a connective tissue or autoimmune disorder.
After these exclusions, we identified 284 patients who had had at least one pretreatment computed tomography (CT) scan of the sinuses. Finally, we identified 100 patients-51 men and 49 women, age 20 to 85 years (mean: 50)-who had had both a pre-and post-treatment CT scan for inclusion in the full analysis.
In addition to demographic data, we compiled information on symptoms at the initial visit, the details of treatment, and changes in symptoms at the first follow-up. We reviewed the pre-and post-treatment sinus CT scans and generated a Lund-Mackay CT score 9 for each scan. Finally, we assessed differences in the prevalence of various symptoms before and after treatment and calculated the number of patients who required surgery.
Of the 100 patients, 17 had been treated with an antibiotic only, 28 with a steroid only, and 55 with both agents.
Statistical analysis. Analysis of variance (ANOVA) was used to test hypotheses involving three groups, and the two-tailed Student t test was used for two groups. Matched-pair t tests were used for comparing data within the same group. Differences in the prevalence of symptoms were analyzed with an extended version of the Fisher exact test. For all tests, a p value of less than 0.05 was considered to represent statistical significance.
Ethical considerations. This study was approved by the Loma Linda University Medical Center's Institutional Review Board.
Results

Concomitant conditions.
Asthma and smoking were not common in the study population; allergic rhinitis was much more prevalent (table 1) .
Antibiotics. The antibiotics used included amoxicillin/clavulanic acid, trimethoprim/sulfamethoxazole, ciprofloxacin, clarithromycin, and moxifloxacin.
Overall, the mean duration of antibiotic therapy was 19.0 days (median: 21; range: 10 to 21) in the antibiotic group and 14.2 days (median: 14; range: 10 to 21) in the combination group. The difference was statistically significant (p < 0.001) (table 1).
Steroids. Two steroids were used in our study: methylprednisolone and prednisone. The two therapies were about evenly split in the steroid group, while methylprednisolone use was significantly more common in the combination group (p = 0.001) (table 1).
The duration of steroid therapy was 6 days for those taking methylprednisolone and 20 days for those on prednisone.
Follow-up. Overall, the mean interval between the pre-and first post-treatment visits was 4.4 weeks (median: 4; range: 2 to 10). There were no statistically significant differences in the length of follow-up among the three groups (table 1) .
Lund-Mackay CT scores. In the study population as a whole, the mean pretreatment Lund-Mackay CT score was 9.1 (median: 9; range: 0 to 20). After treatment, the overall score improved significantly (mean 6.3; median: 6; range: 0 to 17) (p < 0.001). There were Post hoc pairwise comparisons of the prevalence of each symptom among the three groups were not performed because the data were incomplete, and therefore a statistical analysis of these data would have been misleading. However, general trends were apparent, with the combination group experiencing the greatest improvement (figure 2).
Surgery. In all, 40 of the 100 patients underwent surgery; the difference in surgery rates among the three groups was not statistically significant (p = 0.884). Surgery was performed on 9 of the 52 (17.3%) patients who either were followed for at least 1 year or who had had surgery within the first year postoperatively; again, there were no significant differences among the three groups (p = 0.578).
no statistically significant differences among the three groups in either pre-or post-treatment scores (table 2). Significant post-treatment improvement in Lund-Mackay scores was seen in each of the three groups (p ≤ 0.002) (figure 1).
In addition, 53% of the antibiotic group, 46% of the steroid group, and 40% of the combination group exhibited improvements on CT that resulted in Lund-Mackay CT scores of 4 or less post-treatment.
Symptoms. We recorded the pretreatment presence of nasal obstruction, postnasal drip, rhinorrhea, facial pain/pressure, and loss of smell for each patient (table  3) . There was no significant difference in baseline symptoms among the three groups (table 3) .
After treatment, improvement among the three treatment groups differed significantly (p < 0.001). 
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Of those patients who had a post-treatment Lund-Mackay of 4 or less, 33% of the antibiotic group, 46% of the steroid group, and 23% of the combination group eventually underwent surgery.
The mean time to surgery was 12.0 weeks (median 9.7; range: 3 to 49), which did not differ significantly among the three groups (p = 0.122).
Discussion
The role that bacteria play in the chronic inflammatory state seen in CRS is ambiguous and controversial. Also, it is unclear which bacteria clinicians should target with antibiotic treatments. Some authors have suggested that antibiotics merely change the bacterial milieu of CRS rather than eradicating the underlying inflammatory process. 4, 8 Despite the widespread use of antibiotics, the data supporting it in CRS are limited.
Wallwork et al conducted a double-blind, randomized, controlled trial of 64 patients who were treated with systemic antibiotics for CRSsNP. 10 They found that roxithromycin daily for 3 months significantly improved SNOT-20 (Sinonasal Outcome Test-20) scores after 12 weeks, although not after 6 or 24 weeks. Nasal endoscopy scores and saccharine transit times also improved. The most current update on the treatment of CRSsNP with antibiotics was reported in a consensus statement by Orlandi et al. 11 They found insufficient evidence to recommend against or for nonmacrolide antibiotics, and macrolides were offered as an optional treatment.
Antibiotics and steroids have been paired for decades for the treatment of CRS, and the role of steroids in the treatment of CRS with nasal polyps is well established. 12 As a result, steroids are becoming more frequently prescribed for CRSsNP to combat mucosal inflammation, which is the common thread in patients with CRS. In support of the anti-inflammation theory, studies have demonstrated a reduction in inflammatory markers (e.g., IL-8, IL-6, TNF-α), increased ciliary beat frequency, and decreased sinonasal secretion viscosity in CRS patients with macrolide use. 13, 14 Some authors have suggested that controlling the mucosal inflammation, whether it is with steroid or macrolide therapy, will provide relief to patients. 12 A strong recommendation was given to the use of steroids in CRS with nasal polyps due to a reduction in polyp size and consistently significant clinical improvement. 3, 5 However, to the best of our knowledge, no study to date has examined the effect of oral steroids alone for the treatment of CRSsNP. Poetker et al reviewed four case series in which steroids were used along with other therapies, and they concluded that they could not make a recommendation on the use of systemic steroids for treating CRSsNP. 12 The primary outcomes measures in our study were the decrease in Lund-Mackay CT scores, reductions in symptom scores, and the need for surgery. All three treatment groups exhibited a significant decrease in Lund-Mackay CT scores by 15 In our study, the mean pretreatment score was 9.1 and the post-treatment score was 6.3.
In our study, 53% of the antibiotic group, 46% of the steroid group, and 40% of the combination group exhibited improvements on CT that resulted in Lund-Mackay CT scores of 4 or less post-treatment. However, 33, 46, and 23% of these patients, respectively, eventually underwent surgery. One interpretation of this finding is that our CRS "cure" was only temporary and that patients relapsed, which led to the need for surgery.
Lund-Mackay CT scores have been shown to be positively associated with polyp grades, but the association between changes in scores and improvements in clinical symptoms is equivocal. Hopkins et al found that Lund-Mackay CT scores did not correlate strongly with symptom severity represented by SNOT-22 results. 16 However, studies exist that both support and contest these findings, with the consensus leaning more toward the former. [17] [18] [19] [20] Unfortunately, we could not find any literature describing the relationship between Lund-Mackay CT scores and disease severity in CRSsNP. Therefore, we hesitate to speculate on what our finding of significantly decreased Lund-Mackay CT scores after treatment really means in terms of clinical improvement.
In our study, surgery was performed on 40% of all patients and on 77% of those who were followed for more than 1 year or who had surgery within 1 year, with each of the three treatment groups having similar rates. Young et al reported a surgery rate of 52.5% in 80 CRS patients who were treated with 3 weeks of an oral antibiotic, an oral prednisone taper, an intranasal steroid, and saline lavage. 21 McNally et al reported a surgery rate of only 6% in 200 CRS patients who were treated with 4 weeks of an oral antibiotic, nasal corticosteroid, nasal lavage, and topical decongestant. 22 Lal et al 23 reported a 31% surgery rate, while Subramanian et al 24 reported a 10% rate. The rates in these studies vary widely, as do the exact treatment regimens, the duration of treatment, and the presence of nasal poly ps. Although our surgery rate was within the range reported in the literature, it is difficult to make comparisons, since our population included only CRSsNP patients and our treatment modalities were different. However, this wide range of surgical rates may also illustrate the great variability in decisions to pursue surgery, which are based on patient preference, surgeon experience, and different treatment philosophies. 
LIU, RICHARDSON, BERNARD, CHURCH, SEIBERLING
The various controversies over antibiotic use, steroid use, and outcomes measures in the literature were inspirations for our study. Our finding that there was no difference in treatment efficacy among the antibiotic, steroid, and combination groups as represented by changes in Lund-Mackay CT scores and need for surgery indicate a need for further research.
Shortcomings of our study include the use of different types of antibiotic, different durations of antibiotic therapy, the use of two different steroids, and the lack of randomization into treatment groups. However, the effect of using different antibiotics may be insignificant given that studies suggest no difference in efficacy between broad-spectrum antibiotics such as extended-spectrum penicillins (e.g., amoxicillin/clavulanic acid) and fluoroquinolones (e.g., ciprofloxacin). 25, 26 Also, our study did not include the use of a validated symptoms survey, which would have helped to better correlate Lund-Mackay CT scores with clinical symptoms. Finally, there is an intrinsic bias in using CT scans as an outcomes measure. For instance, patients with significant improvement might not have undergone post-treatment CT, thereby leading to a possible underestimation of the effect of treatment. Future prospective studies may also benefit from standardized follow-up for gauging the maintenance of symptom relief and disease recurrence, which have been shown to be common. 8 In conclusion, we found that Lund-Mackay CT scores decreased significantly in patients with CRSsNP after treatment with an antibiotic, a steroid, or combination therapy. However, we found no evidence that any of these treatment modalities was superior to any other in improving CT findings.
